Abstract
It has been shown that prostate cancer is associated with elevated androgen biosynthesis; therefore, inhibiting the activity of Cytochrome P450 17 (CYP17) may prevent progression of prostate cancer. In this study we identified, using in silico and experimental methods, two novel steroidal and non-steroidal lead compounds that inhibit the activity CYP17.
Keywords: Prostate Cancer, Androgen Biosynthesis, Cytochrome P450 enzyme 17R-hydroxylase-17, 20-lyase, Virtual Screening
Letters in Drug Design & Discovery
Title: Discovery of Novel CYP17 Inhibitors for the Treatment of Prostate Cancer with Structure-Based Drug Design
Volume: 6 Issue: 5
Author(s): Pelin Armutlu, Muhuttin Emre Ozdemir, Sule Ozdas, Ibrahim Halil Kavakli and Metin Turkay
Affiliation:
Keywords: Prostate Cancer, Androgen Biosynthesis, Cytochrome P450 enzyme 17R-hydroxylase-17, 20-lyase, Virtual Screening
Abstract: It has been shown that prostate cancer is associated with elevated androgen biosynthesis; therefore, inhibiting the activity of Cytochrome P450 17 (CYP17) may prevent progression of prostate cancer. In this study we identified, using in silico and experimental methods, two novel steroidal and non-steroidal lead compounds that inhibit the activity CYP17.
Export Options
About this article
Cite this article as:
Armutlu Pelin, Ozdemir Emre Muhuttin, Ozdas Sule, Kavakli Halil Ibrahim and Turkay Metin, Discovery of Novel CYP17 Inhibitors for the Treatment of Prostate Cancer with Structure-Based Drug Design, Letters in Drug Design & Discovery 2009; 6 (5) . https://dx.doi.org/10.2174/1570180810906050337
DOI https://dx.doi.org/10.2174/1570180810906050337 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Proteolytic Activation of Angiogenic and Lymphangiogenic Growth Factors in Cancer – Its Potential Relevance for Therapeutics and Diagnostics
Current Medicinal Chemistry Multiple-Target Drugs: Inhibitors of Heat Shock Protein 90 and of Histone Deacetylase
Current Drug Targets Tumor Vasculature Targeted TNFα Therapy: Reversion of Microenvironment Anergy and Enhancement of the Anti-tumor Efficiency
Current Medicinal Chemistry PEDF as an Emerging Therapeutic Candidate for Osteosarcoma
Current Cancer Drug Targets In Situ Gene Therapy for Prostate Cancer
Current Gene Therapy Targeted Drug Delivery and Imaging Using Mobile Milli/Microrobots: A Promising Future Towards Theranostic Pharmaceutical Design
Current Pharmaceutical Design Ligand-receptor Engineering and its Application Towards the Complementation of Genetic Disease and Target Identification
Current Topics in Medicinal Chemistry SUBJECT INDEX TO VOLUME 1
Current Drug Safety Nanosystems in Drug Targeting: Opportunities and Challenges
Current Nanoscience MIF and CD74 - Suitability as Clinical Biomarkers
Mini-Reviews in Medicinal Chemistry The Impact of Tumor Physiology on Camptothecin-Based Drug Development
Current Medicinal Chemistry - Anti-Cancer Agents High Catalytic Activity of Pd Nanoparticles Synthesized from Green Alga Chlorella vulgaris in Buchwald-hartwig Synthesis of N-Aryl Piperazines
Current Organocatalysis Interleukin-6 In Rheumatoid Arthritis - From The Laboratory To The Bedside
Current Pharmaceutical Design New Direct and Frontal Tissue Acquisition Tools for Gene Expression Analysis in Personalized Medicine
Current Pharmacogenomics and Personalized Medicine The Voyage of Natural Chalcone: Isoliquiritigenin
Current Bioactive Compounds Nanoparticle Systems Modulating Myeloid-Derived Suppressor Cells for Cancer Immunotherapy
Current Topics in Medicinal Chemistry Effects of Palmitoylethanolamide and Luteolin in an Animal Model of Anxiety/Depression
CNS & Neurological Disorders - Drug Targets Circular RNAs in Prostate Cancer: Is it Time to Further Explore Liquid Biopsies?
Mini-Reviews in Medicinal Chemistry ERGIC3 Silencing Additively Enhances the Growth Inhibition of BFA on Lung Adenocarcinoma Cells
Current Cancer Drug Targets D-RNAi (Messenger RNA-antisense DNA Interference) as a Novel Defense System Against Cancer and Viral Infections.
Current Cancer Drug Targets